Shares of Aratana Therapeutics Inc. (NASDAQ:PETX) were up 3.4% during trading on Wednesday . The stock traded as high as $6.70 and last traded at $6.67, with a volume of 205,500 shares. The stock had previously closed at $6.45.

Several analysts have commented on PETX shares. William Blair restated an “outperform” rating on shares of Aratana Therapeutics in a report on Tuesday, April 26th. Craig Hallum lowered their target price on shares of Aratana Therapeutics from $11.00 to $7.00 and set a “hold” rating for the company in a report on Wednesday, March 16th. Jefferies Group reissued a “buy” rating and set a $12.00 price target on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Stifel Nicolaus reduced their price target on shares of Aratana Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, March 16th. Finally, Credit Suisse Group AG reissued a “buy” rating on shares of Aratana Therapeutics in a research report on Saturday, April 2nd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Aratana Therapeutics has an average rating of “Buy” and an average price target of $12.81.

The firm’s 50 day moving average is $6.52 and its 200 day moving average is $5.20. The stock’s market capitalization is $232.58 million.

Aratana Therapeutics (NASDAQ:PETX) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by $0.10. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.13 million. During the same quarter in the prior year, the company earned ($0.26) EPS. Aratana Therapeutics’s quarterly revenue was up 6.3% on a year-over-year basis. On average, analysts forecast that Aratana Therapeutics Inc. will post ($1.08) EPS for the current fiscal year.

In other news, insider Ernst Heinen sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $6.72, for a total value of $100,800.00. Following the completion of the sale, the insider now owns 125,494 shares of the company’s stock, valued at approximately $843,319.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Julia A. Stephanus sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 28th. The stock was sold at an average price of $6.25, for a total transaction of $187,500.00. Following the completion of the sale, the insider now directly owns 127,503 shares of the company’s stock, valued at approximately $796,893.75. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Aratana Therapeutics stock. Principal Financial Group Inc. raised its stake in Aratana Therapeutics Inc. (NASDAQ:PETX) by 46.7% during the fourth quarter, Holdings Channel reports. The fund owned 400,000 shares of the biopharmaceutical company’s stock after buying an additional 127,300 shares during the period. Principal Financial Group Inc. owned approximately 1.14% of Aratana Therapeutics worth $2,232,000 at the end of the most recent reporting period.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.